Bridging science, execution and capital in biotech
Technical diligence, development strategy and execution intelligence for advanced therapies.
Active in AI × Biotech through a curated network of specialist collaborators.
THE DEVELOPMENT GAP
Strong science does not guarantee successful development.
Across advanced therapies, programmes stall not because the biology fails, but because of analytical fragility, comparability risk, manufacturing constraints and investment uncertainty.
Analytical fragility
Assays that don’t translate into reliable decisions.
Comparability risk
Changes that create regulatory and clinical uncertainty.
Manufacturing constraints
Processes that don’t scale or sustain.
AI is not execution
Models inform. Execution delivers — and the gap between pilot and scale is wider than most teams expect.
WHERE WE ADD VALUE
We help you navigate the gap between breakthrough and impact.
Built across science, execution, capital and connection to support better decisions, stronger programmes and pathways that hold across geographies. With curated access to AI × biotech and specialist collaborators.
Development strategy
Hands-on advisory across CMC strategy, analytical development, comparability and lifecycle planning from research into clinic.
Technical diligence
Assessment of platform technology, manufacturing readiness and execution risk benchmarked against TRL and MRL frameworks, with AI-aware judgement on modern biotech.
Investment Intelligence
Translation of complex technical reality into the language of capital. Built for funds, family offices and corporate venture teams operating in advanced therapies.
Partnership & Translation Advisory
Structuring collaborations and strategic partnerships that hold under technical, commercial and regulatory pressure by bridging founder realities and investor expectations
Network Catalysis
Connecting founders, capital and institutions at the moments that matter. Curated access via the MCA network, AI × health data collaborators and partner institutions.
UK↔GCC bridge
Active networks across two strategically important biotech geographies by supporting programmes that need to operate, raise capital or partner across both.
TYPICAL ENGAGEMENTS
Focused projects designed to answer critical development, investment or readiness questions.
Analytical & CMC Risk Review
2–3 weeks
A rapid, independent review of analytical strategy, CMC risks and development readiness, designed to inform a critical decision.
TRL & MRL Readiness Assessment
2 weeks
A structured benchmarking review of platform, manufacturing and clinical readiness, calibrated to TRL and MRL frameworks for investment, partnership or grant decisions.